Unibio and their investor SIIG have announced pans to build a plant in Al Jubail which has a potential annual capacity of over 300,000 tonnes of Unibio’s single cell protein, Uniprotein®.

The plant will use Unibio’s vertical loop bioreactor, a continuous-flow fermentation process that replicates nature in converting methane into Uniprotein^®, a high-quality and sustainable single-cell protein for animal feed.

More details on the Unibio website.

BaseLaunch, a platform partnering with scientists and entrepreneurs to launch, fund, and build early biotech ventures, announced today the pharmaceutical giant Pfizer has joined the Basel-based incubator, bringing the total number of leading pharma company partners to seven.

Since its inception almost a decade ago, BaseLaunch has supported 27 biotech companies across various modalities and indications, with several of them having entered Phase II clinical trials. Adding Pfizer as a partner helps BaseLaunch further develop its portfolio companies, which have collectively raised over $1 billion (USD).

River Stone Biotech has strengthened its IP position on their ability to use biology to replace difficult synthetic chemistry.

A new US patent grant, the first of a new patent family, gives the company protection on its unique approach to bioconversion across a range of products. It covers the use of an engineered microbe to improve in vivo conversion of thebaine and oripavine.

At River Stone Biotech, we combine cutting-edge synthetic biology with proven chemical processing to set new standards in molecule manufacturing.

River Stone’s proprietary platform uses flexible intermediates to produce a broad portfolio of specialty molecules. They can cost-effectively produce complex small molecules and fatty acid derivatives both for use as precursors and as final APIs (active pharmaceutical ingredients).

Aida has recently had excellent results validating it’s approach to ensuring that every cancer patient gets the best drugs to treat their tumour. Their proprietary algorithms analyse the expression pattern of more than 300 genes in tumour biopsies. This allows them to provide doctors with advice on which drugs are likely to (and not to) have a beneficial effect.

Recent work on data from the US I-Spy2 trial is the latest evidence of the value of the approach and was accepted as a ‘late-breaking abstract’ at the San Antonio Breast Cancer Symposium.

More details on the Aida website.

Interview with CEO, Neil Goldsmith, covering Sundew’s general approach to the problem of parasites and diseases in aquaculture.

Also covers an interesting collaboration with ECRAM in Uganda.

The full piece is available on The Fish Site

Sundew has completed a collaboration deal with Mote Marine Laboratory & Aquarium.

Under the collaboration, Sundew will be able to develop their natural approach to the damaging algal blooms known as red tides.

More details here.

In an interview with AgFunder News, David Henstrom, Unibio’s CEO, explains the importance of the patented ‘U-Loop®’ bioreactor.

The ‘U-Loop®’ is designed to maximise gas/liquid transfer in continuous biomass fermentation processes. He explains how this new design allows them to expect productivity of 8kg/m³/hour.

This productivity step makes the Unibio process a highly competitive way to produce high-quality protein from methane.

Alentis has completed an oversubscribed Series D round. The round was led by Orbimed and co-led by Novo Holdings and Jeito Capital, with contributions from Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital and Avego Bioscience Capital.

The funds will be used to support the clinical development of Alentis’ pipeline of drugs targeted at solid tumours.

More details on the Alentis website.

Sundew has completed a financing, with EIFO, The Yield Lab Europe and SOSV providing the funds.

The raise was covered (in Danish) by KapitalWatch (payroll).

The Danish pharma giant joins Roche, J&J, CSL Behring, Pureos, CMS, Roivant and Bridge Biotherapeutics in supporting BaseLaunch’s development of innovative biotech companies.

More details on the BaseLaunch website.